Enter your ZIP code:

Please enter a 5 digit zipcode
No results...

Entering your zip code helps us to provide information and results that are more relevant to you.

Your privacy is important to us. By continuing, you agree to our Privacy Policy.





SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-02

Rheumatology
Maria Buethe
SELVA: A Multicenter, Phase 3 Baseline-Controlled Study Evaluating the Safety and Efficacy of PTX-022 in the Treatment of Microcystic Lymphatic Malformations
Immunologic Auto Immune

Study Description

Eligibility

  1. Participant must be at least 6 years of age at time of consent
  2. Participant must have a clinically confirmed superficial/cutaneous microcystic lymphatic malformation

Key

  1. Participants who have vascular malformations that interfere with evaluating the target microcystic lymphatic malformation
  2. Participants with complicated vascular anomalies with severe systemic symptoms that require systemic therapy
  3. The participant's treatment area is mainly in any wet mucosa or within the orbital rim
  4. Participants who are pregnant or planning to become pregnant
A female nurse attentively holds a tablet, ready to assist with patient care and medical information.

Interested in Participating in this Trial?

Thank you for your interest with our team.

One of our specialists will be in contact with you soon.